Cytokine Shifts and Tolerance in Experimental Autoimmune Encephalomyelitis

Immunologic Research

Volumn 28, Issue 3, 2003, Pages 223-239

  Chitnis, Tanuja ^a   Khoury, Samia J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cytokines; Experimental autoimmune encephalomyelitis; Multiple sclerosis; STAT; T cell; T helper cell; Tolerance

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; JANUS KINASE; LYMPHOTOXIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEOLIPID PROTEIN; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 13; RECOMBINANT INTERLEUKIN 4; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; STAT PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT6 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; APOPTOSIS; ASTROCYTE; B LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL INFILTRATION; CELL MIGRATION; CELL POLARITY; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMYELINATING DISEASE; DENDRITIC CELL; DIMERIZATION; DISEASE SEVERITY; DOWN REGULATION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MICROGLIA; MONOCYTE; NATURAL KILLER CELL; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL; TH1 CELL; TH2 CELL; TH3 CELL; UPREGULATION;

ANIMALS; CYTOKINES; DNA-BINDING PROTEINS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNE TOLERANCE; MICE; MULTIPLE SCLEROSIS; MYELIN PROTEINS; RATS; SIGNAL TRANSDUCTION; TH1 CELLS; TH2 CELLS; TRANS-ACTIVATORS;

EID: 0347756797     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:28:3:223     Document Type: Review

References (121)

1. Brosnan CF, Cannella B, Battistini L, et al.: Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995;45(6Suppl 6):S16-S21.
2. Balashov KE, Smith DR, Khoury SJ, et al.: Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997;94(2):599-603.
3. Comabella M, Balashov K, Issazadeh S, et al.:Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998;102(4): 671-678.
4. Balashov KE, Comabella M, Ohashi T, et al.: Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS. Neurology 2000;55(2):192-198.
5. Karni A, Koldzic DN, Bharanidharan P, et al.: IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol 2002;125(1-2): 134-140.
6. Khademi M, Wallstrom E, Andersson M, et al. : Reduction of both pro-and anti-inflammatory cytokines after 6 months of Interferon beta-1a treatment of multiple sclerosis. J Neuroimmunol 2000;103(2):202-210.
7. Lunemann JD, Aktas O, Gniadek P, et al.: Down-regulation of transforming growth factor-beta1 in interferon-betal a-treated MS patients. Neurology 2001; 57(6): 1132-1134.
8. Wandinger KP, Sturzebecher CS, Bielekova B, et al.: Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001;50(3):349-357.
9. Dhib-Jalbut S.: Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002;58(8 Suppl 4):S3-S9.
10. Yong VW: Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 2002;59(6):802-808.
11. Duda PW, Schmied MC, Cook SL, et al.: Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000;105(7):967-976.
12. Karp CL, van Boxel-Dezaire AH, Byrnes AA, et al.: Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr Opin Neurol 2001;14(3):361-368.
13. Weiner HL, Cohen JA: Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002;8(2):142-154.
14. Zhang J, Markovic-Plese S, Lacet B, et al.: Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med, 1994;179(3):973-984.
15. Hafler DA, Kent SC, Pietrusewicz MJ, et al.: Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci 1997;835(1):120-131.
16. Fukaura H, Kent SC, Pietrusewicz MJ, et al.: Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996;98(1):70-77.
17. Minguela A, Torio A, Marin L, et al. : Implication of Th1, Th2, and Th3 cytokines in liver graft acceptance. Transplant Proc 1999;31(1-2):519-520.
18. Powell MB, Mitchell D, Lederman J, et al.: Lympho-toxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 1990;2(6): 539-544.
19. Zamvil SS, Nelson PA, Mitchell DJ, et al.: Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition. J Exp Med 1985; 162(6):2107-2124.
20. Khoury SJ, Hancock WW, Weiner HL: Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992;176(5):1355-1364.
21. Issazadeh S, Navikas V, Schaub M, et al.: Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. J Immunol 1998;161(3): 1104-1112.
22. Issazadeh S, Ljungdahl A, Hojeberg B, et al.: Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression forinterleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J Neuroimmunol 1995; 61(2):205-212.
23. Chen Y, Kuchroo VK, Inobe J, et al.: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994:265(5176): 1237-1240.
24. Kuchroo VK, Das MP, Brown JA, et al.: B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80(5):707-718.
25. Cua DJ, Hinton DR, Stohlman SA:Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. J Immunol 1995;155(8): 4052-4059.
26. Khoruts A, Miller SD, Jenkins MK: Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol, 1995;155(10):5011-5017.
27. Lafaille JJ, Keere FV, Hsu AL, et al.: Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997;186(2):307-312.
28. Wensky A, Marcondes MC, Lafaille JJ: The role of IFN-gamma in the production of Th2 subpopulations: implications for variable Th2-mediated pathologies in autoimmunity. J Immunol, 2001;167(6):3074-3081.
29. Issazadeh S, Mustafa M, Ljungdahl A, et al.: Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 1995;40(5):579-590.
30. Begolka WS, Vanderlugt CL, Rahbe SM, et al.: Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 1998;161(8):4437-4446.
31. Renno T, Taupin V, Bourbonniere L, et al.: Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 1998;12(6):376-389.
32. Ferber IA, Brocke S, Taylor-Edwards C, et al.: Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996;156(1):5-7.
33. Lublin FD, Knobler RL, Kalman B, et al.: Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity, 1993; 16(4):267-274.
34. Krakowski M, Owens T: Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996;26(7):1641-1646.
35. Konieczny BT, Dai Z, Elwood ET, et al.: IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 1998;160(5):2059-2064.
36. Hassan AT, Dai Z, Konieczny BT, et al: Regulation of alloantigen- mediated T-cell proliferation by endogenous interferon-gamma: implications for long-term allograft acceptance. Transplantation 1999;68(1):124-129.
37. Badovinac VP, Tvinnereim AR, Harty JT: Regulation of antigen-specific CD8+ T cell homeostasis by perform and interferon-gamma. Science 2000;290(5495): 1354-1358.
38. Chu CQ, Wittmer S, Dalton DK: Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med 2000;192(1):123-128.
39. Willenborg DO, Fordham SA, Staykova MA, et al.: IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J Immunol 1999;163(10):5278-5286.
40. Liu Y, Janeway CA Jr.: Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med 1990;172(6):1735-1739.
41. van der Veen RC, Dietlin TA, Dixon Gray J, et al,: Macrophage-derived nitric oxide inhibits the proliferation of activated T helper cells and is induced during antigenic stimulation of resting T cells. Cell Immunol 2000;199(1):43-49.
42. Sallusto F, Lenig D, Mackay CR, et al.: Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998; 187(6):875-883.
43. Vanguri P, Farber JM: IFN and virus-inducible expression of an immediate early gene, crg-2/IP-10, and a delayed gene, I-A alpha in astrocytes and microglia. J Immunol 1994;152(3):1411-1418.
44. Tran EH, Prince EN, Owens T: IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol 2000:164(5): 2759-2768.
45. Chitnis T, Najafian N, Benou C, et al.: Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001;108(5):739-747.
46. Issazadeh S, Lorentzen JC, Mustafa MI, et al.: Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-beta. J Neuroimmunol, 1996;69(1-2):103-115.
47. Kuroda Y, Shimamoto Y: Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol 1991;34(2-3):159-164.
48. Selmaj K, Raine CS, Cross AH: Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30(5):694-700.
49. Ruddle NH, Bergman CM, McGrath KM, et al.: An anti-body to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172(4):1193-1200.
50. Probert L, Akassoglou K, Pasparakis M, et al.: Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA 1995;92(24):11294-11298.
51. Selmaj KW, Raine CS: Tumor necrosis factor mediates myelin andoligodendrocyte damage in vitro. Ann Neurol 1988;23(4):339-346.
52. Akassoglou K, Bauer J, Kassiotis G, et al.: Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 1998;153(3):801-813.
53. Liu J, Marino MW, Wong G, et al.: TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4(1):78-83.
54. Frei K, Eugster HP, Bopst M, et al.: Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997;185(12):2177-2182.
55. Bachmann R, Eugster HP, Frei K, et al.: Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am J Pathol 1999;154(5): 1417-1422.
56. Suvannavejh GC, Lee HO, Padilla J, et al.: Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol 2000; 205(1):24-33.
57. Selmaj K, Papierz W, Glabinski A, et al.: Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 1995;56(2):135-141.
58. Korner H, Lemckert FA, Chaudhri G, et al.: Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur J Immunol 1997;27(8):1973-1981.
59. Speiser DE, Sebzda E, Ohteki T, et al.: Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 1996; 26(12):3055-3060.
60. Bright JJ, Musuro BF, Du C, et al.: Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. J Neuroimmunol 1998:82(1): 22-30.
61. Jander S, Stoll G.: Differential induction of interleukin-12, interleukin-18, and interleukin-Ibeta converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat. J Neuroimmunol 1998; 91(1-2):93-99.
62. Smith T, Hewson AK, Kingsley CI, et al.: Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 1997;150(6): 1909-1917.
63. Leonard JP, Waldburger KE, Goldman SJ: Prevention of experimental autoimmune encephalomyelitis by anti-bodies against interleukin 12. J Exp Med 1995;181(1): 381-386.
64. Segal BM, Shevach EM: IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med 1996;184(2): 771-775.
65. Waldburger KE, Hastings RC, Schaub RG, et al.: Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. Am J Pathol 1996;148(2):375-382.
66. Leonard JP, Waldburger KE, Goldman SJ: Regulation of experimental autoimmune encephalomyelitis by interleukin-12. Ann N Y Acad Sci 1996;795:216-226.
67. Campbell IL, Stalder AK, Akwa Y, et al.: Transgenic models to study the actions of cytokines in the central nervous system. Neuroimmunomodulation, 1998; 5(3-4): 126-135.
68. Segal BM, Dwyer BK, Shevach EM: An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998; 187(4):537-546.
69. Gran B, Zhang GX, Yu S, et al.: IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002;169(12):7104-7110.
70. Cua DJ, Sherlock J, Chen Y, et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421(6924):744-748.
71. Okamura H, Tsuti H, Komatsu T, et al.: Cloning of a new cytokine that induces IFN-gamma production by T cells [see comments]. Nature 1995;378(6552):88-91.
72. Ushio S, Namba M, Okura T, et al.: Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996;156(11):4274-4279.
73. Tone M, Thompson SA, Tone Y, et al.: Regulation of IL-18 (IFN-gamma-inducing factor) gene expression. J Immunol 1997;159(12):6156-6163.
74. Matsumoto S, Tsuji-Takayama K, Aizawa Y, et al.: Interleukin-18 activates NF-kappaB in murine T helper type 1 cells. Biochem Biophys Res Commun 1997; 234(2):454-457.
75. Jacobson NG, Szabo SJ, Weber-Nordt RM, et al.: Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med 1995; 181(5):1755-1762.
76. Chang JT, Segal BM, Nakanishi K, et al.: The costimulatory effect of IL-18 on the induction of antigen-specific IFN-gamma production by resting T cells is IL-12 dependent and is mediated by up-regulation of the IL-12 receptor beta2 subunit. Eur J Immunol 2000; 30(4): 1113-1119.
77. Yoshimoto T, Takeda K, Tanaka T, et al.: IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998;161(7):3400-3407.
78. Xu D, Chan WL, Leung BP, et al.: Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med 1998;188(8): 1485-1492.
79. Fantuzzi G, Reed DA, Dinarello CA: IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest 1999;104(6):761-767.
80. Kennedy MK, Torrance DS, Picha KS, et al.: Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992;149(7): 2496-2505.
81. Okuda Y, Sakoda S, Yanagihara T: The pattern of cytokine gene expression in lymphoid organs and peripheral blood mononuclear cells of mice with experimental allergic encephalomyelitis. J Neuroimmunol 1998;87(1-2): 147-155.
82. Okuda Y, Sakoda S, Bernard CC, et al.: The development of autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein is associated with an upregulation of both proinflammatory and immunoregulatory cytokines in the central nervous system. J Interferon Cytokine Res 1998;18(6):415-421.
83. Mendel I, Katz A, Nozak N, et al.: Interleukin-6 functions in autoimmune encephalomyelitis: a study in genetargeted mice. Eur J Immunol 1998;28(5): 1727-1737.
84. Diab A, Zhu J, Xiao BG, et al.: High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. J Neuropathol Exp Neurol 1997;56(6):641-650.
85. Gijbels K, Brocke S, Abrams JS, et al.: Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol Med 1995; 1(7):795-805.
86. Okuda Y, Sakoda S, Fujimura H, et al.: IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis. J Neuroimmunol 1999; 101(2):188-196.
87. Eugster HP, Frei K, Kopf M, et al.: IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998; 28(7):2178-2187.
88. Samoilova EB, Horton JL, Hilliard B, et al.: IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 1998; 161(12):6480-6486.
89. Karpus WJ, Gould KE, Swanborg RH: CD4+ suppressor cells of autoimmune encephalomyelitis respond to T cell receptor-associated determinants on effector cells by interleukin-4 secretion. Eur J Immunol 1992;22(7): 1757-1763.
90. Racke MK, Bonomo A, Scott DE, et al.: Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med, 1994;180(5): 1961-1966.
91. Bettelli E, Das MP, Howard ED, et al.: IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10-and IL-4-deficient and transgenic mice. J Immunol 1998;161(7): 3299-3306.
92. Shaw MK, Lorens JB, Dhawan A, et al.: Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1997;185(9):1711-1714.
93. Liblau R, Steinman L, Brocke S: Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Int Immunol 1997;9(5):799-803.
94. Falcone M, Rajan AJ, Bloom BR, et al.: A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J Immunol 1998;160(10):4822-4830.
95. Inobe J, Slavin AJ, Komagata Y, et al.: IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol 1998;28(9): 2780-2790.
96. Rott O, Fleischer B, Cash E: Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994;24(6):1434-1440.
97. Cua DJ, Groux H, Hinton DR, et al: Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med 1999;189(6): 1005-1010.
98. Cannella B, Gao YL, Brosnan C, et al.: IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 1996;45(6):735-746.
99. Koo GC, Manyak CL, Dasch J, et al.: Suppressive effects of monocytic cells and transforming growth factor-beta on natural killercell differentiation in autoimmune viable motheaten mutant mice. J Immunol, 1991;147(4): 1194-1200.
100. Stevens DB, Gould KE, Swanborg RH: Transforming growth factor-beta 1 inhibits tumor necrosis factor-alpha/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. J Neuroimmunol 1994;51(1):77-83.
101. Shull MM, Ormsby I, Kier AB, et al.: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359(6397):693-699.
102. Johns LD, Flanders KC, Ranges GE, et al.: Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J Immunol 1991;147(6):1792-1796.
103. Kuruvilla AP, Shah R, Hochwald GM, et al.: Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991;88(7):2918-2921.
104. Santambrogio L, Hochwald GM, Saxena B, et al.: Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J Immunol 1993;151(2): 1116-1127.
105. Racke MK, Sriaram S, Carlino J, et al.: Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 2. J Neuroimmunol 1993;46(1-2): p. 175-183.
106. Thorbecke GJ, Umetsu DT, deKruyff RH, et al.: When engineered to produce latent TGF-beta1, antigen specific T cells down regulate Th1 cell-mediated autoimmune and Th2 cell-mediated allergic inflammatory processes. Cytokine Growth Factor Rev 2000;11(1-2): 89-96.
107. Chen LZ, Hochwald GM, Huang C, et al.: Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. Proc Natl Acad Sci USA 1998;95(21):12516-12521.
108. Johns LD, Sriram S: Experimental allergic encephalomyelitis: neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease. J Neuroimmunol 1993;47(1):1-7.
109. Wyss-Coray T, Borrow P, Brooker MJ, et al.: Astroglial overproduction of TGF-beta 1 enhances inflammatory central nervous system disease in transgenic mice. J Neuroimmunol 1997;77(1):45-50.
110. Cash E, Minty A, Ferrara P, et al.: Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J Immunol 1994;153(9): 4258-4267.
111. Kaplan MH, Schindler U, Smiley ST, et al.: Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996;4(3):313-319.
112. Takeda K, Tanaka T, Shi W, et al.: Essential role of Stat6 in IL-4 signalling. Nature 1996;380(6575):627-630.
113. Thierfelder WE, van Deursen JM, Yamamoto K, et al.: Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996; 382(6587):171-174.
114. Kaplan MH, Sun YL, Hoey T, et al.: Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996;382(6587):174-177.
115. Barbulescu K, Becker C, Schlaak JF, et al.: IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Immunol 1998;160(8):3642-3647.
116. Robinson D, Shibuya K, Mui A, et al.: IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997;7(4):571-581.
117. Chitnis T, Najafian N, Abdallah KA, et al.: CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001;107(5):575-583.
118. Schaub M, Issazadeh S, Stadibauer TH, et al.: Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 1999; 96(2):158-166.
119. Khoury SJ, Galloon L, Verburg RR, et al.: Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1996;157(8):3700-3705.
120. Khoury SJ, Akalin E, Chandraker A, et al.: CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995;155(10): 4521-4524.
121. Zhang X, Izikson L, Liu L, et al.: Activation of CD25(+) CD4(+) regulatory T cells by oral antigen administration. J Immunol 2001;167(8):4245-4253.